Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study confirms Upadacitinib's safety for inflammatory bowel disease in korean patients

NCT ID NCT06459297

Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This completed study looked at how safe and effective upadacitinib (RINVOQ) is for Korean adults with moderate to severe ulcerative colitis or Crohn's disease. About 600 participants were followed for up to 52 weeks while taking the drug as prescribed by their doctor. The main goal was to track serious side effects and changes in disease activity.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
upadacitinib (RINVOQ)
What this could lead to
If results are positive, this could confirm that upadacitinib is a safe and effective option for managing moderate to severe ulcerative colitis and Crohn's disease in Korean patients.
What could go wrong
This is a post-marketing surveillance study, not a controlled trial, so results may be less definitive. Side effects like serious infections or allergic reactions are possible with upadacitinib.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

105 people

The number who actually took part.

Started

Jun 2024

Finished

Dec 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult participants with ulcerative colitis or Crohn's Disease

Ages

19 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants diagnosis with ulcerative colitis or Crohn's Disease suitable for the treatment with Upadacitinib. * Participants prescribed upadacitinib in accordance with the approved local label. Exclusion Criteria: * Participants with any contraindication to Upadacitinib. * Participants currently participating in another clinical research not including observational study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Crohn's disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Crohn disease inflammatory bowel disease ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Crohn's disease Ulcerative colitis

Contacts and locations

Locations

  • Chosun University Hospital /ID# 269990

    Gwangju, Jeonranamdo, 61453, South Korea

  • Ewha Womans University Medical Centre /ID# 269776

    Seoul, Seoul Teugbyeolsi, 07985, South Korea

  • Gangnam Severance Hospital /ID# 270020

    Seoul, Seoul Teugbyeolsi, 06273, South Korea

  • Hallym University Kangnam Sacred Heart Hospital /ID# 270013

    Seoul, Seoul Teugbyeolsi, 07441, South Korea

  • Inje University - Ilsan Paik Hospital /ID# 269995

    Goyang-si, Gyeonggido, 10380, South Korea

  • Keimyung University Dongsan Hospital /ID# 269775

    Daegu, Gyeongsangbuk-do, 42601, South Korea

  • Kyung Hee University Hospital /ID# 270003

    Dongdaemun-gu, Seoul Teugbyeolsi, 02447, South Korea

  • Seoul Songdo Hospital /ID# 270009

    Junggu, 04597, South Korea

  • SoonChunHyang University Hospital Cheonan /ID# 270015

    Cheonan-si, Chungcheongnam-do, 31151, South Korea

  • The Catholic University of Korea, Daejeon St. Mary's Hospital /ID# 267843

    Daejeon, Daejeon Gwang Yeogsi, 34943, South Korea

  • The Catholic University of Korea, Seoul St. Marys Hospital /ID# 270014

    Seoul, Seoul Teugbyeolsi, 06591, South Korea

  • Ulsan University Hospital /ID# 270006

    Ulsan, Ulsan Gwang Yeogsi, 44033, South Korea

  • Yeungnam University Medical Center /ID# 269992

    Daegu, 42415, South Korea

  • Yonsei University Health System Severance Hospital /ID# 268865

    Seoul, Seoul Teugbyeolsi, 03722, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.